CAR T-Cell Therapy: Pediatric Patients With Relapsed and Refractory Acute Lymphoblastic Leukemia
Autor: | Beth Ely, Diane Baniewicz, Colleen Callahan |
---|---|
Rok vydání: | 2017 |
Předmět: |
Male
medicine.medical_specialty Pediatrics Adolescent T-Lymphocytes Lymphoblastic Leukemia medicine.medical_treatment Cell- and Tissue-Based Therapy Receptors Antigen T-Cell Multidisciplinary team 03 medical and health sciences Education Nursing Continuing 0302 clinical medicine Refractory Recurrence Humans Medicine 030212 general & internal medicine Child Intensive care medicine Survival rate General Environmental Science Chimera business.industry Treatment options Immunotherapy Precursor Cell Lymphoblastic Leukemia-Lymphoma Chimeric antigen receptor 030220 oncology & carcinogenesis General Earth and Planetary Sciences CAR T-cell therapy Female business |
Zdroj: | Clinical Journal of Oncology Nursing. 21:22-28 |
ISSN: | 1538-067X 1092-1095 |
DOI: | 10.1188/17.cjon.s2.22-28 |
Popis: | Background Immunotherapy provides a promising treatment option for children and adolescents with refractory or relapsed acute lymphoblastic leukemia (ALL). . Objectives This article presents a hospital's experience with providing chimeric antigen receptor (CAR) T-cell therapy, followed by a detailed discussion of the trajectory of treatment provided for pediatric patients and their families. . Methods Clinical experience in delivering care to pediatric patients undergoing CAR T-cell therapy is described. Care coordination, patient and family assessment and education, and post-CAR T-cell infusion monitoring are presented. . Findings Of 59 patients having been treated with CAR T-cell therapy at the authors' institution, 93% had a complete response at day 28. The 12-month relapse-free survival rate is 55%. A multidisciplinary team of skilled clinicians is recommended to support patient and family needs throughout screening, treatment, and follow-up while coordinating care with the referring oncologist. |
Databáze: | OpenAIRE |
Externí odkaz: |